Biotricity, Inc. (BTCY) Q4 2025 Earnings Conference Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 16.5% YoY revenue increase and a significant improvement in gross margins. Operating expenses have decreased, and there is progress towards profitability with positive adjusted EBITDA in Q4. The Q&A section reveals some uncertainties, but overall, management's optimism and strategic initiatives, like international expansion and data monetization, are positive. Despite some vague timelines, the company's strong financials and strategic plans outweigh the risks, suggesting a positive stock price movement.
Key Financial Performance
Revenue for Q4 2025 $3.7 million, a 16.5% increase year-over-year. This growth is attributed to the efficacy of strategic initiatives and the transition to a flat-fee, subscription-based model.
Revenue for Fiscal Year 2025 $13.8 million, a 14.3% increase from $12.1 million in the prior year. The increase is due to strong market adoption of cardiac monitoring devices and the subscription-based model.
Gross Profit for Q4 2025 $3 million, a 31% increase from $2.3 million in the prior year period. The improvement is due to the expansion of recurring technology fee revenue, AI efficiencies, and monitoring cost structure improvements.
Gross Margin for Q4 2025 80.4%, an improvement of over 890 basis points compared to 71.5% in the prior year. This is attributed to recurring technology fee revenue and cost efficiencies.
Operating Expenses for Fiscal Year 2025 $13 million, a 24.5% decrease from $17.2 million in the prior year. The reduction is due to cost-cutting measures, including a 30.2% decrease in SG&A expenses and a 19.2% reduction in R&D expenses.
Net Loss for Fiscal Year 2025 $11.9 million, compared to $14.9 million in the prior year. The improvement is due to revenue growth, cost management, and operational efficiencies.
Net Loss for Q4 2025 $2 million, compared to $5.3 million in the prior year. The improvement is despite growth-related expenses and rising variable interest rates.
Adjusted EBITDA for Q4 2025 $438,000 (positive), compared to a loss in the prior year. This improvement is due to cost management and operational efficiencies.
Adjusted EBITDA for Fiscal Year 2025 A loss of just under $1 million, compared to a loss of $7.8 million in fiscal 2024. The improvement reflects progress towards breakeven and profitability.
Operating Highlights
Cardiac AI cloud platform expansion: Expanded platform leveraging over 1 trillion heartbeats of anonymized data, powered by partnerships with Amazon AWS and Google's TensorFlow. Pursuing FDA clearance for AI clinical model.
Biocore Pro: Expanded sales of next-generation cardiac monitoring device with cellular connectivity. High adoption rates and positive feedback for usability and patient compliance.
HeartSecure: Launched direct-to-consumer heart health screening service targeting $1.1 billion home heart health market.
GPO partnerships: Strategic alliances with 3 top group purchasing organizations, providing access to 90% of U.S. hospitals.
Health Canada and Saudi Arabia approvals: Received Health Canada approval for Biocore device and regulatory approval in Saudi Arabia, opening new revenue opportunities.
Revenue growth: Q4 revenue increased by 16.5% YoY to $3.7 million; fiscal year revenue rose by 14.3% to $13.8 million.
Gross margin improvement: Gross margin for Q4 improved to 80.4%, up from 71.5% in the prior year.
Cost reductions: Operating expenses decreased by 24.5% YoY, with SG&A down 30.2% and R&D down 19.2%.
Diversification into pulmonary and neurology: Expanded into new fields through partnerships with home-based diagnostic companies.
Path to profitability: Achieved positive adjusted EBITDA of $438,000 in Q4, with significant improvements in operating cash flows and reduced losses.
Risk or Challenges
Long Sales Cycles and Rollout Periods: The sales associated with strategic alliances with GPOs are characterized by long sales cycles and rollout periods, which could delay revenue realization and impact cash flow.
Regulatory Approvals and Compliance: The company is pursuing FDA clearance for its AI clinical model and has recently received regulatory approvals in Canada and Saudi Arabia. Delays or challenges in obtaining or maintaining these approvals could hinder market expansion and product deployment.
Economic Uncertainties and Rising Interest Rates: The company faces challenges associated with rising variable interest rates, which have impacted net losses and could affect future financial stability.
Dependence on Strategic Partnerships: The company's reliance on partnerships with industry giants like Amazon, AWS, and Google, as well as GPOs, poses risks if these partnerships face disruptions or fail to deliver expected benefits.
Market Penetration Challenges: Despite significant progress, the company is still in the process of penetrating hospitals and large clinics, which could limit revenue growth if not achieved effectively.
Operational Cost Management: While operating expenses have decreased, the company must continue to manage costs effectively to maintain profitability and positive cash flow.
Global Market Expansion Risks: The company is expanding into international markets like Saudi Arabia and Canada. Challenges in these markets, such as cultural, regulatory, or competitive factors, could impact success.
Guidance & Outlook
Revenue Growth: The company anticipates further revenue growth in the coming quarters, driven by the adoption of its flagship device, Biocore Pro, which is targeted for use in hospitals and large clinics.
Profitability: Biotricity is on a path to achieving profitability in the next few quarters, supported by positive operating cash flows and improvements in adjusted EBITDA.
Market Expansion: The company has received regulatory approvals in Saudi Arabia and Health Canada, enabling entry into new markets. Additionally, partnerships with three major GPOs provide access to 90% of U.S. hospitals.
Product Development: Biotricity is advancing the commercialization of its Biocore, Bioflux, and Biocare products, with plans to expand into other jurisdictions in 2026 and beyond.
Strategic Initiatives: The company is diversifying into pulmonary and neurology fields through partnerships and has launched HeartSecure, a direct-to-consumer heart health screening service targeting the $1.1 billion home heart health market.
Shareholder Return Plan
The selected topic was not discussed during the call.
Key Q&A
Earnings Word Cloud
BTCY Transcript
The earnings call highlights strong revenue growth, improved profitability, and strategic market expansion. While there are risks, such as regulatory hurdles and market penetration challenges, the company's positive free cash flows, improved gross profit margins, and strategic partnerships contribute to a favorable outlook. The absence of negative sentiment in the Q&A session further supports a positive sentiment. Despite a net loss, the reduction in losses and positive EBITDA indicate progress towards profitability, leading to a predicted stock price movement in the 2% to 8% range over the next two weeks.
The earnings call highlights strong financial performance with a 16.5% YoY revenue increase and a significant improvement in gross margins. Operating expenses have decreased, and there is progress towards profitability with positive adjusted EBITDA in Q4. The Q&A section reveals some uncertainties, but overall, management's optimism and strategic initiatives, like international expansion and data monetization, are positive. Despite some vague timelines, the company's strong financials and strategic plans outweigh the risks, suggesting a positive stock price movement.
The earnings call highlights significant revenue growth, improved gross margins, and reduced operating expenses, indicating strong financial performance. Despite challenges in market expansion and interest rates, the company's strategic initiatives in AI and new market penetration are promising. The Q&A session confirms management's proactive approach to growth and profitability, with no unclear responses. The positive sentiment is reinforced by the company's path to profitability and successful cost management, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
BTCY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
